Clinical trial NCT03755570: How is COGNItive Function Affected by Cardiac Resynchronisation Therapy?
Official title: How is COGNItive Function Affected by Cardiac Resynchronisation Therapy?
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Cognitive Impairment
Cognitive Change
Heart Failure, Systolic
Heart Failure
Cognitive Impairment, Mild
Left Ventricular Dysfunction
Left Ventricular Systolic Dysfunction
Systolic Dysfunction
Systolic Heart Failure
Keywords: Cognitive Impairment
Left Ventricular Systolic Dysfunction
Heart Failure
Cardiac Resynchronisation Therapy
Implantable Cardioverter-Defibrillator
Pacemaker
CRT
ICD
PPM
Lead sponsor: Royal Cornwall Hospitals Trust
Sponsor class: OTHER
First posted: 2018-11-28
Enrollment: 198
Sex: ALL
Minimum age (years): 20
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Heart failure patients (left ventricular ejection fraction (LVEF) \<35%) receiving an Cardiac Implantable Electronic Device (CIED), including Cardiac Resynchronisation Therapy (CRT), an Implantable Cardioverter Defibrillator (ICD) or a Permanent Pacemaker (PPM).

Brief summary: The primary objective of COGNI-CRT is to assess whether Cardiac Resynchronisation Therapy (CRT) can improve cognitive function in patients with systolic HF (LVEF ≤35%), when compared to a control group of patients implanted with an Implantable Cardioverter-Defibrillator (ICD) or a permanent pacemaker (PPM) with systolic HF (LVEF ≤35%).

This clinical investigation is a prospective, single-centre cohort study. Each participant will be followed for 6 months. The study will collect data over 3 years; 2.5 years for enrolment and 6 months until the last participant completes the last 6-month follow-up visit.

N.B: COGNI-CRT does NOT affect the patient's care pathway - the patients who will be selected for participation are those who have already been referred for the device implant. The ONLY difference to the patient's care pathway caused by COGNI-CRT is the addition of a battery of cognitive function tests, which involves asking the patient questions and asking them to complete questionnaire-like cognitive tests.

NTpro-BNP levels, NYHA classification and LVEF will be measured prior to device implantation and at 6-months post-implant to assess the device's impact on the participant's heart failure (and CRT response). N.B: NT-proBNP, NYHA classification and LVEF are all parts of the patient's standard care pathway, COGNI-CRT is just utilising the data collected as part of the investigation.

The main study arm and control group allows COGNI-CRT to assess 3 potential outcomes for patients with severe HF (LVEF \<35%):

1. Cognitive function is not improved by CRT, ICDs or PPMs
2. Cognitive function can be improved by the assurance of rate control offered by CRT, ICDs and PPMs
3. Cognitive function can be improved by the assurance of ventricular synchronisation and rate control provided by the additional left ventricular lead in CRT devices.

Detailed description: Purpose:

The purpose of this clinical investigation is to assess whether cardiac resynchronisation therapy (CRT) can improve cognitive function in patients with systolic heart failure (Left Ventricular Ejection Fraction (LVEF) ≤35%), when compared to a control group of patients implanted with an implantable cardioverter-defibrillator (ICD) or permanent pacemaker (PPM) with systolic heart failure (LVEF ≤35%).

Design:

This clinical investigation is a prospective, single-centre cohort study. The study will be conducted at the Royal Cornwall Hospital Trust (RCHT) in Cornwall, England. Subjects will be followed for 6 months.

Cognitive performance will be assessed in patients pre- and post-CRT implant (Group A). An ICD and PPM control group (Group B) will also be assessed using the same battery of cognitive function tests to ensure any difference in cognitive function which is identified between pre- and post- CRT implant is due to the CRT therapy, and not due to a placebo effect (which can be especially powerful with implanted devices) or due to a learning effect (i.e. patients tested on the second occasion might improve their scores because they have had more practice).

N.B: COGNI-CRT does NOT affect the patient's care pathway - the patients who will be selected for participation are those who have already been referred for the device implant. The ONLY difference to the patient's care pathway caused by COGNI-CRT is the addition of a battery of cognitive function tests, which involves asking the patient questions and asking them to complete questionnaire-like cognitive tests.

LVEF, NT-proBNP and New York Heart Association (NYHA) classification data which is collected prior to device implantation and at 6-months post-implant will be utilised for analysis to measure response to CRT and to assess difference between the main arm and control group.

Arms in the study will be:

* Group A: Participants implanted with a CRT who are eligible according to the inclusion/ exclusion criteria
* Group B: Participants implanted with an ICD or a PPM who are eligible according to the inclusion / exclusion criteria

Objectives:

Primary objective: To assess whether CRT can improve cognitive function in patients with systolic heart failure (LVEF ≤35%), when compared to a control group of patients implanted with an ICD or PPM with systolic heart failure (LVEF ≤35%).

Secondary Objectives:

* To assess whether CRT can improve cognitive function
* To assess whether ICD and PPM therapy can improve cognitive function
* To assess if the level of improvement in cognitive function correlates to LVEF improvement / stability and/or NYHA improvement /stability and/or NT-proBNP level reduction (CRT response).

Subject Population:

The subject population enrolled in this investigation will comprise of male and female patients aged 20-89 years old. These subjects are patients who are willing to provide informed consent and meet the specific eligibility criteria. A minimum of 198 participants will be enrolled in this investigation.

Data for this study will be collected at:

* Enrolment
* Pre-Assessment for CRT, ICD or PPM Implantation
* Cardiac Implantable Electronic Device (CIED) Implant
* Post-Implant 6-Week Device Check (For device optimisation)
* Post-Implant 6-Month Device Follow-Up Visit After completing the Post-Implant 6-Month Device Follow-Up Visit, the patient will have completed his/her participation in the study.

Devices Used:

Implanted CRT-P, CRT-D, ICD and PPM devices may include Biotronik, Boston Scientific, Medtronic and St Jude Medical.

Patient Screening:

Patients who are referred to RCHT for CRT, ICD or PPM implantation with systolic heart failure (LVEF ≤35%) will be screened prior to Pre-Assessment by the clinical team. Prospective patients will be afforded sufficient time to consider participation in COGNI-CRT.

Cognitive Tests Used to Evaluate Cognitive Function:

To be Performed Only At Pre-Assessment:

1. Test of Premorbid Functioning (TOPF): TOPF provides the participant with a list of 70 words that have atypical grapheme to phoneme translations. The participant must attempt to read the list aloud so pronunciation of the words can be assessed. This tests IQ and memory as the participant must be familiar with the words, rather than being able to spell out a word they do not know. It takes approximately 10 minutes to complete

   To be Performed at Pre-Assessment and at the Post-Implant 6-Month Device Follow-Up Visit:
2. Hospital Anxiety and Depression Scale (HADS): The test consists of 14 multiple-choice questions, each attempting to ascertain about the frequency the participant has felt a certain symptom within the last 7 days. There are 4 answers to choose from which range from suffering from the symptom "nearly all the time" to "not at all" and are graded 0-3 depending on the participant's answer.
3. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Consisting of 12 sections, to evaluate 5 types of cognitive function: immediate memory; visuospatial/ constructional; attention; language and delayed memory.
4. Frontal Assessment Battery (FAB): The test has 6 neuropsychological tasks which involve asking the participant questions, for example "In what way are a banana and an orange alike?", and learning simple actions in response to hand taps or movements.
5. Trail Making Test (TMT) Parts A \& B: Both parts of TMT involve circles dotted over a piece of paper, the circles for Part A are marked with the numbers 1 - 25 and the patient must draw a line connecting the numbers in ascending order, i.e. "1-2-3-4-5-6..." etc. Part B involves numbers and letters dotted around the page, from 1-13 and from A-L. The patient must connect the numbers and letters in ascending order, alternating between numbers and letters, i.e. "1-A-2-B-3-C..." etc

Response to CRT Measures will be measured prior to device implantation and at the 6-month follow-up device follow-up clinic:

LVEF: LVEF will be measured prior to device implant to assess the patient's heart function, and at the Post-Implant 6-Month Device Follow-Up Visit.

NT-proBNP: NT-proBNP levels from the patient's routine blood tests prior to device implantation and at the Post-Implant 6-Month Device Follow-Up Visit where blood testing is routine for heart failure patients every 6 months.

NYHA: A NYHA scale assessment will be performed during the screening clinics prior to device implant, and at the Post-Implant 6-Month Device Follow-Up Visit using the standardised NYHA questions designed for the purpose of this trial.

N.B: The above 3 tests (LVEF, NT-proBNP and NYHA classification) are performed routinely as part of the patient standard care pathway for heart failure, and this data will be utilised for analysis in this trial. The tests are NOT performed for the purpose of COGNI-CRT.

Device Optimisation:

At the post-implant 6-week device follow-up check, all efforts will be made to ensure the device is optimised as much as is possible, and the patient listed for MDT if problems are encountered to attempt to resolve problems.

Data Analysis:

Data will be tested for normality. Tests for group differences will be used to compare cognitive function between patients before and after CRT implant, and in the control group before and after ICD or PPM implant. Tests for group differences will also be used in comparison of the LVEF values, BNP results, NYHA classification, QRS duration, percentage biventricular pacing and BP measurements. Sample size calculations have estimated the required CRT sample size to power the study to be 99 participants (with a 95% confidence interval and a 5% margin of error). The expectation is for 99 patients to sign the informed consent and complete follow-up = 99 CRT participants. The control group will aim to enrol a similar figure to the main study group, a further 99 ICD and PPM participants. 99 CRT patients + 99 ICD or PPM patients = 198 patients are expected to be enrolled and complete the study.

Eligibility criteria: Inclusion Criteria:

* Undergoing implant of a CRT system with an LVEF of ≤35% (main group), or ICD or PPM system with an LVEF of ≤35% (control group)
* Are 20 - 89 years of age
* Be able to provide written informed consent prior to investigational related procedure, and be willing and able to comply with the described protocols and follow-up schedules listed in the PIS
* Be literate to a level in which the cognitive function tests can be completed effectively
* Mental capacity to provide informed consent and undertake cognitive function tests
* Geographically stable and able to return for the Post-Implant 6-Month Device Follow-Up Visit

Exclusion Criteria:

* Are ≤19 years of age (due to specifications outlined in cognitive function test requirements)
* Are ≥90 years of age (due to specifications outlined in cognitive function test requirements)
* Are pregnant at time of enrolment
* Is participating in an investigational drug investigation
* Be experiencing a condition at the time of data collection which affects mental capacity (lack capacitiy), such as dementia, Alzheimer's, psychosis, schizophrenia (excluding depression and anxiety).
* Recent Cerebral Vascular Event (CVE) which may have affected cognitive function
* Heavy substance abuse, drugs or alcohol

Primary outcomes:
measure: Change in cognitive function at 6 months post-implant
timeFrame: 6 months
Secondary outcomes:
measure: Change in left ventricular ejection fraction (LVEF) at 6 months
timeFrame: 6 months
measure: Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) Test at 6 months
timeFrame: 6 months
measure: Change in New York Heart Association (NYHA) Functional Classification
timeFrame: 6 months
Other outcomes:
Locations:
city: Truro
country: United Kingdom
facility: Royal Cornwall Hospital NHS Trust
state: Cornwall
Study officials:
affiliation: Royal Cornwall Hospital NHS Trust
name: Hannah Ford, BSc (Hons)
role: PRINCIPAL_INVESTIGATOR
References: